BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3702499)

  • 1. Cardiovascular risk--what should be measured?
    Frantz ID
    Mayo Clin Proc; 1986 May; 61(5):396-8. PubMed ID: 3702499
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of apolipoprotein levels in clinical practice.
    Grundy SM; Vega GL
    Arch Intern Med; 1990 Aug; 150(8):1579-82. PubMed ID: 2116784
    [No Abstract]   [Full Text] [Related]  

  • 3. [Determination of apolipoproteins AI and B: diagnostic significance and immunochemical methods].
    Marcovina S
    Ric Clin Lab; 1984; 14 Suppl 2():75-94. PubMed ID: 6442453
    [No Abstract]   [Full Text] [Related]  

  • 4. [Ischemic heart disease and plasma apoproteins B and A-1].
    Kurdanov KhA; Metel'skaia VA; Polesskiĭ VA; Matveeva LS; Perova NV
    Ter Arkh; 1984; 56(12):17-9. PubMed ID: 6441299
    [No Abstract]   [Full Text] [Related]  

  • 5. Fasting specimens not required for routine measurement of plasma apolipoproteins A-I and B.
    Hester J; Shephard MD; Walmsley RN; White GH
    Ann Clin Biochem; 1989 Jul; 26 ( Pt 4)():374-5. PubMed ID: 2504103
    [No Abstract]   [Full Text] [Related]  

  • 6. Apolipoprotein assays for the diagnosis of hyperlipidemias.
    Rosseneu M; Bury J
    Prog Clin Biol Res; 1988; 255():143-54. PubMed ID: 3124129
    [No Abstract]   [Full Text] [Related]  

  • 7. [Measurement of apolipoproteins is better than routinely measured traditional lipids].
    Kallner A; Estonius M
    Lakartidningen; 2006 Mar 8-14; 103(10):753-6, 758. PubMed ID: 16610202
    [No Abstract]   [Full Text] [Related]  

  • 8. [Circulating immune complexes and apolipoproteins in ischemic heart disease].
    Osipov SG; Keĭnova EE; Titov VN; Iaroshevskaia FM; Eremeeva MV
    Kardiologiia; 1986 Apr; 26(4):67-70. PubMed ID: 3712956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable incremental value of standard and nonstandard lipids for coronary heart disease risk assessment in elderly adults: the Three City Study.
    Straczek C; Marti-Soler H; Tafflet M; Perier MC; Dupuy AM; Tzourio C; Barberger-Gateau P; Empana JP
    J Am Geriatr Soc; 2013 Jul; 61(7):1234-6. PubMed ID: 23855861
    [No Abstract]   [Full Text] [Related]  

  • 10. [Apolipoproteins and the vascular risk in hemodialyzed subjects].
    Allegra V; Mengozzi G; Spulzaro P; Piani C; Di Marco F; Vasile A
    Minerva Urol Nefrol; 1986; 38(4):435-41. PubMed ID: 3589890
    [No Abstract]   [Full Text] [Related]  

  • 11. Apolipoprotein B and apolipoprotein AI as predictors of coronary artery disease.
    Sniderman AD
    Can J Cardiol; 1988 Jul; 4 Suppl A():24A-30A. PubMed ID: 3141025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoproteins A-I and B as predictors of angiographically defined coronary artery disease.
    Reinhart RA; Gani K; Arndt MR; Broste SK
    Arch Intern Med; 1990 Aug; 150(8):1629-33. PubMed ID: 2116785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid and apolipoprotein levels in patients with ischaemic heart disease. A comparative study in Plzen and Moscow.
    Steinerová A; Perova NV; Metel'skaya VA; Topolcan O; Karlícek V; Polívková V
    Cor Vasa; 1989; 31(4):257-63. PubMed ID: 2509134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral coronary risk indicators and apolipoproteins A-I and B in young Finnish children: cross-sectional and predictive associations.
    Räikkönen K; Keltikangas-Järvinen L; Solakivi T
    Prev Med; 1990 Nov; 19(6):656-66. PubMed ID: 2263576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determination of apolipoproteins: An important tool for prevention and treatment of cardiovascular diseases].
    Wiklund O
    Lakartidningen; 2007 May 14-29; 104(20-21):1623-4. PubMed ID: 17564272
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prevalence and concurrence of several coronary risk factors in a sample of adolescents at a high school in the community of Madrid].
    Sánchez-Muniz J; Cuesta C; Castro A
    Rev Clin Esp; 1990 Feb; 186(3):119-23. PubMed ID: 2356351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoproteins and coronary artery disease.
    Kottke BA; Zinsmeister AR; Holmes DR; Kneller RW; Hallaway BJ; Mao SJ
    Mayo Clin Proc; 1986 May; 61(5):313-20. PubMed ID: 3702492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?
    Manfroi WC; Zago AJ; Campos M; Alves A; Brisolara ML; de Souza J; Candiago RH; Kirschnick L; Ribeiro L; Ordovás K; Leitão C; Cruz R
    Arq Bras Cardiol; 1999 Jun; 72(6):657-68. PubMed ID: 10752172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lipoprotein particles LpA-I, LpA-I: A-II and LpB in coronary artery disease].
    Calvo C; Olmos A; Ulloa N; Bustos A; Toledo L; Durán D; Naveas R
    Rev Med Chil; 2000 Jan; 128(1):9-16. PubMed ID: 10883517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A simple procedure for the simultaneous determination of apolipoproteins AI and B using rocket immunoelectrophoresis].
    Oswald B; Winkler L; Schlag B; Dargel R
    Z Med Lab Diagn; 1984; 25(8):411-6. PubMed ID: 6441367
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.